Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Russell who wrote (437)	12/4/1997 11:50:00 PM
From: RavBruce	Respond to of 1580

Sure, the ability to get a piece of Prozac's sales have a lot of people looking at Merck. But, management did say in a press release or conference call that they are sure they will make next year's concensus figures. Since I do not trade Merck(I only own a ton of it and do not plan to sell since my children will go to college on it just as I did after a 200 share investment turned into 5000 shares over time)I usually ignore earnings forecasts, etc. I realize that many institutional investors follow these things carefully as do traders. That may explain some of the jump. It still has not reached last year's high although we are within a few points. $2,000,000,000+ of R and D means we have lots more in store over the next few years. If you own Merck for the short-term, you may be concerned that some drugs are going off patent. I am not sure why you would buy Merck only to trade it. That's enough rambling for me, Bruce